匹多莫得辅助治疗传染性单核细胞增多症的疗效

Curative effect of pidotimod on adjuvant treatment of infectious mononucleosis

目的分析细胞免疫调节剂匹多莫得辅助治疗儿童传染性单核细胞增多症(IM)的疗效。方法选取2014年3月至2016年3月在西安市儿童医院接受治疗的100例传染性单核细胞增多症儿童为研究对象,将其随机分为对照组及试验组,给予对照组患儿常规对症治疗,在此基础上对试验组患儿采用细胞免疫调节剂匹多莫得实施辅助治疗,比较分析两组研究对象的治疗效果、症状体征持续时间及患儿的EBV-DNA定量和EBV-CA-IgM的阳性率。结果试验组的治疗有效率(96.00%)明显高于对照组(70.00%),两组比较差异具有统计学意义(χ~2=6.875,P<0.05)。试验组的住院时间、发热、白细胞计数、异型淋巴细胞、肝功转氨酶指标、咽峡炎、颈部淋巴结肿大、肝脾肿大症状恢复正常时间与对照组比较明显缩短,差异均有统计学意义(t值分别为12.361、8.472、14.546、14.283、13.784、8.756、8.512、9.135,均P<0.05)。试验组患者治疗2周后的EBV-DNA定量阳性率及2个月后EBV-CA-IgM的阳性率均明显低于对照组,差异均有统计学意义(χ~2值分别为7.423、8.852,均P<0.05)。结论细胞免疫调节剂匹多莫得实施辅助治疗IM的效果显著,安全可靠,值得临床推广。

Objective To analyze the curative effect of cell immunomodulator pidotimod on adjuvant treatment of childhood infectious mononucleosis（ IM）. Methods Totally 100 cases of childhood IM were selected as research objects during the period of March 2014 to March 2016,and they were divided into experimental group and control group randomly. The control group was given conventional treatment,and the experimental group was given cell immunomodulator pidotimod for adjuvant treatment on the basic of conventional treatment. The treatment effect,duration of symptoms and signs,EBV-DNA quantity and positive rate of EBV-CA-IgM of two groups were analyzed and explored. Results The effective rate of the experimental group（ 96. 00%） was obviously higher than that of the control group（ 70. 00%）,and the difference was significant（ χ~2 = 6. 875,P 0. 05）. The hospital stay,duration of fever,and the recovery time of WBC,atypical lymphocytes, transaminase of liver function, angina,cervical lymph nodes enlargement,hepatosplenomegaly were remarkably reduced in the experimental group compared to the control group with statistical significance（ t value was 12. 361,8. 472,14. 546,14. 283,13. 784,8. 756,8. 512 and 9. 135,respectively,all P 0. 05）. The positive rate of EBV-DNA quantity 2 weeks later and that of EBV-CA-IgM 2 months later in the experimental group were significantly lower than those in the control group（ χ~2 value was7. 423 and 8. 852,respectively,both P 0. 05）. Conclusion Cell immunomodulator pidotimod obtains remarkable curative effect for adjuvant treatment of IM. It promotes the recovery of vital signs of cases and alleviates the symptoms with safety and reliability. It is worthy of clinical promotion.